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Prospective Screening in Multiple Endocrine Neoplasia Type 1

Britt Skogseid,* and Kjell Oberg*

To assess the age of clinically detectable onset of multiple endocrine neoplasia type 1 (MEN I), 88
members offour families were invited to participate in a ten-year biochemical screening program.
Evidence for clinically detectable MEN 1 was found 'in adolescence. Pancreatic endocrine dysfunction constituted the presenting lesion in a majority ofthese individuals. The age at diagnosis
of pancreatic endocrine tumors averaged 25 years and was lowered by almost m-o decades by
prospective investigation. Furthermore, the penetrance ofthe pancreatic endocrine and parathyroid
lesions equaled the penetrance found in autopsy studies. The use ofa standardized meal stimulation
test with the measurement of serum pancreatic polypeptide (PP) and gastrin responses resulted in
diagnostic sensitivities of 75% and 100%, respectively. In addition to basal serum PP and insulin
values, the proinsulin level was predictive for early pancreatic involvement in MEN 1. Serum gastrin
was another useful tumor marker but only in the patients with pancreatic tumors diagnosed outside
the prospective investigation. Two of the four MEN I kindreds selectedfor the screening investigation
displayed homogeneity within families with respect to the profile of peptide excess and malignant
potential of the pancreatic endocrine lesion, while the remaining kindreds demonstrated variable
MEN 1 traits. (Henry Ford Hosp Med J 1992;40:167-70]

M

ultiple endocrine neoplasia type 1 (MEN 1) is an autosomal dominantiy inherited disorder encompassing neoplasia of the parathyroid glands, anterior pituitary, and endocrine pancreas (1). The MEN 1 gene (MENl) has been mapped
to chromosome 1 lql3 (2). The function of the gene seems to be
masked by the existence of a normal counterpart (2-5). This suggests that MENl represents an inactivated suppressor gene
(anti-oncogene), which could normally be involved in regulating differentiation of the endocrine pancreas, the parathyroids,
and the anterior pituitary gland. The pituitary tumors in MEN 1
have not been evaluated, but loss of the wild-type allele in MEN
1 parathyroids and pancreatic micro- and macroadenomas has
been demonstrated as well as loss of constitutional heterozygosity in about one-third of sporadic parathyroid adenomas (2-5).
Recent advances in mapping of the MEN 1 gene, which have
narrowed the target region (6), now permit identification of individuals at risk for MEN 1 with a high degree of accuracy. It is
therefore increasingly important to clarify the natural course of
the syndrome, die early characteristics of the developing lesions, and the expected utility of available diagnostic measures
in order to design an optimal screening program.

Material and Methods
All individuals above 10 years of age in four MEN 1 kindreds
were offered repeated biochemical screening investigations for
10 years. The screening program and references to methods
used (7-20) in analyzing different hormones are listed in Table
1. At the first investigation, 56 of 62 members participated (27
women and 29 men, mean age 33 years, range 10 to 75 years),
while during the last screening 80 of 88 were subjected to the
tests (37 women and 43 men, mean age 35 years, range 10 to 85
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years). Patients with known MEN 1 trait prior to first screening
and those widi lesions recognized at the first screening were denoted as nonprospectively diagnosed patients. Individuals without biochemical abnormalities at the first screening who later
developed evidence of MEN 1 were considered as prospectively
diagnosed patients. A patient displaying an MEN 1 lesion at first
screening, and therefore defined as a nonprospectively diagnosed patient, could develop a previously undetected or new lesion which would then be considered a prospectively diagnosed
MEN 1 lesion.
Diagnostic criteria
Basal fasting hormone levels were considered elevated ifthe
reference range was exceeded. The meal stimulation test was
considered abnormal if the serum pancreatic polypeptide (PP) or
gastrin response to the meal was more than two standard deviations higher than the mean response in control subjects (20). An
MEN 1 family member was considered affected by hyperparathyroidism (HPT) if albumin-corrected serum calcium and/
or serum parathyroid hormone were elevated. A diagnosis of pituitary tumor was made if an elevated serum prolactin or diumal
serum growth hormone and/or positive sella radiology were observed. An MEN 1 family member was considered affected by a
pancreatic endocrine lesion if basal hormone markers and/orthe
meal test were abnormal in combination with radiological evidence of a pancreatic tumor. In the absence of positive radiol-
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Table 1
Biochemical Screening Program for MEN 1
Hematology (hemoglobin concentration, leukocyte and
platelet count)
Sedimentation rate
Blood glucose
Albumin-corrected serum calcium
Serum creatinine
Serum sodium
Serum potassium
Serum aspartate aminotransferase
Serum alanine aminotransferase
Serum parathyroid hormone (7)
Serum prolactin (8)
Serum growth hormone (9)
Serum insulin (10)
Serum C-peptide (11)
Serum proinsulin (12)
Serum pancreatic polypepfide (13)
Serum gastrin (14)
Serum calcitonin (15)
Serum human chorionic gonadotrophin subunits a and p (16)
Plasma glucagon (17)
Plasma somatostatin (18)
Plasma vasoactive intestinal polypeptide (19)
Meal stimulation test (20)
References are noted in parentheses.

Ogy, repeated and progressive elevation of hormonal markers
was required for diagnosis of a pancreatic endocrine tumor.

Results and Comments
Total prevalence of MEN 1 lesions
The most common lesion was HPT, found in 90% of the patients. Pituitary tumors were detected in 19% of affected family
members, a low figure compared to frequencies found in autopsy studies (60%) (1). Pancreatic endocrine involvement was,
however, demonstrated biochemically in 75% of MEN 1 patients. This is the highest frequency reported in screening studies and nears thefindingsin autopsy materials (1).
Age at diagnosis of the trait
Seven individuals without biochemical evidence of MEN 1 at
first investigation developed MEN 1 abnormalities during follow-up, at an age of 18 years ± 4 standard deviations (range 12 to
25 years). This contrasted with a nonprospectively diagnosed
MEN 1 trait at a mean age of 36 ± 13 years (range 15 to 63
years). The age at diagnosis was lowered by approximately two
decades by screening. In three of the seven patients the first detectable lesion was the pancreatic lesion; in two others parathyroid and pancreatic endocrine involvement was demonstrated
concurrently. In contrast to previous reports (21,22), HPT was
found to be the presenting lesion in only two of the patients.
Age at diagnosis of HPT and pituitary tumors
HPT was recognized prospectively in seven individuals at a
mean age of 19 ± 5 years (range 12 to 28 years) (Table 2). The
age of HPT diagnosis was significantly decreased by screening
since the nonprospectively-made diagnoses averaged 38 ± 14
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Table 2
Number, Sex, and Age (Years) at Diagnosis of Primary
Hyperparathyroidism (HPT), Pituitary Tumors, and
Pancreatic Endocrine Tlimors in Nonprospectively
Diagnosed Patients and Prospectively Diagnosed Patients
Number
Total
F/M
Nonprospectively Diagnosed:
HPT
Pituitary tumor
Pancreatic lesion
Prospectively Diagnosed:
HPT
Pituitary tumor
Pancreatic lesion

Mean Age
(Years)

Age Range
(Years)

22
5
15

10/12
4/1
5/10

38
.39
44

15-63
16-59
25-71

7
1
9

1/6
0/1
l/S

19
24
25

12-28
24
16-38

Nonprospectively diagnosed = diagnosed prior to or at the first screening; prospectively
diagnosed = diagnosed during the subsequent 10-year investigation.

years. The age of diagnosis in the nonprospectively screened
group was similar to that reported by others (21-23). Only one
patient developed pituitary lesions during the 10-year followup; a 24-year-old male displayed biochemical signs of acromegaly. The five patients with nonprospectively detecied pituitary lesions had a mean age at diagnosis of 39 ± 17 years in accord with previous reports (21-23) (Table 2).
Age at diagnosis of pancreatic endocrine tumors
One of the most striking findings in this screening study was
the young age at onset of the pancreatic endocrine lesion in nine
individuals diagnosed by prospective screening. Six of these
nine individuals have had pancreatic surgery in which pancreatic tumors were found (24). The age at biochemical diagnosis
averaged 25 ± 8 years (range 16 to 38 years) which was significandy lower (P < 0.005) than in the 15 patients with nonprospectively-recognized pancreatic tumors (a mean of 44 ± 16
years of age [Table 2]). Others have found the mean age at penetrance of the pancreatic endocrine tumors of the MEN 1 syndrome to be the fourth and fifth decades of life (22,23).
Symptoms
In all cases of prospectively diagnosed lesions, the patients
were asymptomatic except for one female with a pancreatic endocrine lesion who had experienced mild hypoglycemic symptoms and weight gain during breast feeding. The individuals
with nonprospectively diagnosed lesions, however, showed
clinical symptoms related to their MEN 1 lesions. The majority
of patients with nonprospectively diagnosed HPT had histories
of nephrolithiasis, and those with nonprospective pituitary lesions had amenorrhea and infertility as well as headaches, dizziness, and a reduction of their visual fields. Furthermore, the nonprospectively diagnosed pancreatic lesions caused tumor-related symptoms in 11 of the 15 patients. The most frequently
displayed classical endocrine manifestations were the Zollinger-Ellison, hypoglycemia, and watery diarrhea syndromes.
Nausea and/or abdominal pain was observed in three individu-
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als. Transition from one syndrome to another occurred in three
ofthe 15 patients during follow-up.
Biochemical markers for pancreatic endocrine tumors
The serum PP was elevated in 67% of both prospectively and
nonprospectively diagnosed individuals (Table 3). The secretion of PP is subject to great intra- and interindividual variation
(25) and increases with age (21,25). However, the upper reference range (0.4 ng/mL) for basal semm PP in our laboratory is
based on measurements in 45 healthy individuals with a mean
age of 39 years (range 20 to 60 years) (13) and is, therefore,
comparable to the present MEN 1 study. Among the patients
with nonprospectively diagnosed pancreatic endocrine tumors,
basal semm gastrin and PP were equally useful. In patients with
prospectively diagnosed lesions, however, serum gastrin was elevated in only two of nine individuals. Vasen et al (23) used serum gastrin as a screening marker for pancreatic involvement
and their mean age at diagnosis was 38 years. Thus, gastrin production from pancreatic endocrine tumors could be a result of a
long-standing cell proliferation or the development of duodenal
neuroendocrine tumors with gastrin production (26). Semm insulin and proinsulin levels were elevated in approximately half
of the patients, respectively, and constituted equally useful
markers in the prospective and nonprospective patient groups.
Serum hCG alpha and beta subunits have been considered indicative of malignant tumors in neuroendocrine tissue (16,27). In
our series semm hCG alpha and/or beta was elevated more often
(26% and 33%) among the patients with nonprospectively diagnosed pancreatic tumors in comparison to the individuals with
prospectively diagnosed lesions (11% and 0%). Plasma glucagon had a sensitivity of 37% among the young tumor patients
and was somewhat lower (27%) in the group with nonprospectively diagnosed lesions. All other pancreatic tumor markers
were within normal limits in the group of patients with prospectively diagnosed pancreatic tumors.
In agreement with others (20,28) meal-stimulated semm PP
distinguished MEN 1 pancreatic endocrine tumors better than
measurements of basal semm PP alone (20). In one patient, both
the semm gastrin and PP response to the test meal normalized
after resection of three PP-producing tumors of the endocrine
pancreas even though no gastrin immunoreactivity was demonstrated in the resected specimen. All 15 of the patients with nonprospectively diagnosed pancreatic tumors and 75% of those
with prospectively recognized pancreatic lesions had abnormal
peptide responses to the test meal. Thus, an abnormal meal stimulation test was the most useful marker for pancreatic endocrine
involvement in the MEN 1 patients, making it appropriate for
use in screening young asymptomatic individuals.
Morbidity, mortality, and familial entities
The individuals with prospectively diagnosed lesions were,
with few exceptions, asymptomatic at diagnosis and during follow-up (mean 3.5 years). Among patients with nonprospectively diagnosed lesions, severe endocrine symptoms were common and one-third of the patients with pancreatic endocrine tumors had metastases at diagnosis. Only one of the nine patients
with prospectively diagnosed pancreatic involvement had me-
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Table 3
Sensitivity of Tiimor Markers Among Patients
with Nonprospectively and Prospectively Diagnosed
Pancreatic Endocrine Tiimors
Nonprospective

S-PP
S-gastrin
S-proinsulin
S-insulin
S-HCG a/p
P-glucagon
P-VIP
Meal test

Prospective

(%)

(%)

67

46
26/33
27

67
22
56
56
11/0
37

2(1
10(1

75

67
.S8

0

tastases, and this individual died at age 40 from tumor progression. Whether this apparent reduced morbidity in patients subjected to early diagnosis and intervention will persist during
long-term follow-up remains to be evaluated. At present, no significant difference in survival (Kaplan-Meyer life-table method) between the two patient categories has been found, although
the follow-up period is short.
In two of the kindreds, the peptide profile and malignant behavior of the tumors were homogeneous within families. In one
of these families the MEN 1 trait was invariably benign and 75%
of the patients with pancreatic involvement had the ZollingerEllison syndrome, whereas in the other family eight (89%) of
the nine individuals with pancreatic endocrine lesions displayed
insulin-proinsulin hypersecretion. This overrepresentation of a
specific hormone secretion was significant (P < 0.05, Student /
test). In the latter family three individuals died before the age of
55 and another two had metastases at the time of diagnosis.
Within the remaining two kindreds peptide hormone excess and
malignant potential in affected individuals were variable. These
results suggest that in families with prominent malignant potential of the pancreatic lesions, surgery is indicated at early asymptomatic stages of the disease. In addition, peptide hormone excess alone is not satisfactory in selecting patients for surgery.
Others have reported syndrome-dependent policies for surgical
intervention (29,30).

Conclusion
The MEN 1 trait is clinically detectable in adolescents. The
pancreatic endocrine dysfunction constitutes the presenting lesion in a majority of affected individuals and the penetrance of
this lesion approximated findings in autopsy studies. Semm PP,
insulin, proinsulin, and glucagon were the most useful basal
markers for diagnosis of pancreatic tumors, but a meal test with
measurements of semm PP and gastrin responses enhanced the
detection of early endocrine pancreatic tumors in asymptomatic
young individuals. Reliable markers for malignant transformation are still lacking and therefore the malignant potential must
be evaluated for each family and each individual. A decision for
surgical intervention in MEN 1 cannot be based on the hormone
profile only.
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